Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Current Deferred Revenue: 2016-2025

Historic Current Deferred Revenue for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $26.4 million.

  • Tg Therapeutics' Current Deferred Revenue rose 190.32% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.4 million, marking a year-over-year increase of 190.32%. This contributed to the annual value of $11.4 million for FY2024, which is 7409.21% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Current Deferred Revenue is $26.4 million, which was up 10.41% from $23.9 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Current Deferred Revenue peaked at $26.4 million during Q3 2025, and registered a low of $152,000 during Q4 2023.
  • In the last 3 years, Tg Therapeutics' Current Deferred Revenue had a median value of $6.9 million in 2023 and averaged $9.3 million.
  • As far as peak fluctuations go, Tg Therapeutics' Current Deferred Revenue crashed by 69.60% in 2023, and later skyrocketed by 7,409.21% in 2024.
  • Tg Therapeutics' Current Deferred Revenue (Quarterly) stood at $600,000 in 2021, then fell by 16.67% to $500,000 in 2022, then crashed by 69.60% to $152,000 in 2023, then spiked by 7,409.21% to $11.4 million in 2024, then surged by 190.32% to $26.4 million in 2025.
  • Its Current Deferred Revenue stands at $26.4 million for Q3 2025, versus $23.9 million for Q2 2025 and $17.1 million for Q1 2025.